Clinical trial NCT04483739: Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)
Official title: Phase III Study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) Versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Multiple Myeloma
Keywords: newly diagnosed MM
autologous stem cell transplantation
Isatuximab
Carfilzomib
Lenalidomide
Dexamethasone
Lead sponsor: European Myeloma Network B.V.
Sponsor class: NETWORK
Collaborators: name: EMN Trial Office S.r.l. Impresa Sociale
name: Sanofi
name: Amgen
First posted: 2020-07-23
Enrollment: 302
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This protocol is a phase III study designed to compare the efficacy and the safety of Isa-KRd induction, transplant, Isa-KRd post ASCT consolidation and Isa-KRd light consolidation vs KRd induction, transplant, KRd post ASCT consolidation and KRd light consolidation After confirmation of eligibility criteria patients will be randomized to one of the 2 treatment groups in a 1:1 randomization ratio.

Detailed description: This is a open-label randomized phase III study that enrolls newly diagnosed MM patient eligible for high-dose chemotherapy and ASCT. Patients will be randomized at enrolment (1:1, stratification according to ISS Stage \[3 levels: I vs II vs III\] and cytogenetic risk FISH \[2 levels: high-risk vs standard risk/missing\] based on presence of t(4;14), t(14;16), and/or del 17p)) into 2 treatment arms: -ARM A: induction with 4 cycles of Isatuximab-Carfilzomib-Lenalidomide-dexamethasone (Isa-KRd) followed by cyclophophamide and stem cell collections, chemotherapy with Melphalan 200 mg/m2 followed by ASCT (Mel200-ASCT), 4 cycles of Isa-KRd post ASCT consolidation and 12 cycles of Isatuximab-Lenalidomide-Carfilzomib-dexamethasone (IsaKRd) light consolidation; ARM B: induction with 4 cycles of Carfilzomib-Lenalidomide-dexamethasone (KRd) followed by cyclophophamide and stem cell collections, chemotherapy with Melphalan 200 mg/m2 followed by ASCT (Mel200-ASCT), 4 cycles of KRd post ASCT consolidation and 12 cycles of Carfilzomib-Lenalidomide-dexamethasone (KRd) light consolidation. Details of all treatments (dose and schedule) are given in paragraph 8. After light consolidation patients are allowed to receive Lenalidomide maintenance as per standard of care.

Eligibility criteria: Inclusion Criteria:

* Patient with newly diagnosed multiple myeloma and eligible to ASCT.
* Patient is, in the investigator's opinion, willing and able to comply with the study visits and procedures required per protocol.
* Patient has provided written informed consent in accordance with federal, local, and institutional guidelines prior to initiation of any study-specific activities or procedures. Subject does not have kind of condition that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent and patient is, in the investigator(s) opinion, willing and able to comply with the protocol requirements.
* Monoclonal plasma cells in the bone marrow ≥10% or presence of a biopsy proven plasmacytoma and documented multiple myeloma satisfying at least one of the calcium, renal, anemia, bone (CRAB) criteria or biomarkers of malignancy criteria:
* CRAB criteria:

  * Hypercalcemia: serum calcium \>0.25 mmol/L (\>1 mg/dL) higher than upper limit of normal (ULN) or \>2.75 mmol/L (\>11 mg/dL)
  * Renal insufficiency: creatinine clearance \<40mL/min or serum creatinine \>177 μmol/L (\>2 mg/dL)
  * Anemia: hemoglobin \>2 g/dL below the lower limit of normal or hemoglobin \<10 g/dL
  * Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT
* Biomarkers of Malignancy:

  * Clonal bone marrow plasma cell percentage ≥60%
  * Involved: uninvolved serum FLC ratio ≥100
  * \>1 focal lesion on magnetic resonance imaging (MRI) studies
* Patient is 18 - 70 years old and is eligible for autologous stem cell transplantation
* Patient has measurable disease as defined by any one of the following:

  * Serum monoclonal paraprotein (M-protein) level ≥1.0 g/dL or urine M-protein level ≥200 mg/24 hours; or
  * Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin FLC ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio.
* Life expectancy ≥ 3 months
* ECOG status ≤2
* Clinical laboratory values meeting the following criteria during the Screening Phase:

  * Adequate hepatic function, with serum (alanine aminotransferase) ALT ≤ 2.5 times the upper limit of normal (ULN), AST (aspartate transaminase) ≤ 2.5 x the ULN
  * Serum direct bilirubin ≤ 1.5 ULN) (except in subjects with congenital bilirubinemia, such as Gilbert syndrome, direct bilirubinemia ≤ 1.5 ULN)
  * Absolute neutrophil count (ANC) ≥ 1.0 × 109/L
  * Platelet count ≥ 75× 109/L (≥ 50× 109/L if myeloma involvement in the bone marrow is \> 50%) and no platelet infusion in the 1 week prior to screening platelet count
  * Creatinine clearance (CrCl) ≥ 30 mL/minute. Creatinine clearance should be calculated using eGFR (Modified Diet in Renal Disese \[MDRD\])
  * Corrected serum calcium ≤ 13.5 mg/dL (3.4 mmol/L)
  * LVEF ≥ 40%. 2-D transthoracic echocardiogram (ECHO) is the preferred method of evaluation. Multigated Acquisition Scan (MUGA) is acceptable if ECHO is not available.
* Females of childbearing potential (FCBP)\* complies with the conditions of the Pregnancy Prevention Plan, including confirmation that she has an adequate level of understanding and must agree to ongoing pregnancy testing and to practice contraception or true abstinence. FCBP must use a highly effective and an additional barrier contraception method simultaneously for 4 weeks before starting therapy, during treatment and dose interruptions and for 5 months after the last dose of study drugs.
* Male subjects must agree to practice contraception if sexually active with FCBP during the treatment and for 5 months after the last dose of study drugs. Males must agree to refrain from donating sperm for at least 90 days after the last dose of carfilzomib and for at least 5 months after the last dose of isatuximab.
* \*Note 1: a FCBP is a woman who:
* has achieved menarche at some time point,
* has not undergone a hysterectomy or bilateral oophorectomy or,
* has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).
* Note 2: true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

Exclusion Criteria:

* Previous treatment with anti-myeloma therapy (does not include radiotherapy, biphosphonates, or a single short course of steroid ≤ to the equivalent of dexamethasone 40 mg/day for 4 days).
* Patients with non-secretory MM unless serum free light chains are present and the ratio is abnormal or a plasmacytoma with minimum largest diameters of \> 2 cm.
* Patients with plasma cell leukemia, amyloidosis, Waldenstrom Disease, POEMS syndrome
* Meningeal involvement of multiple myeloma
* Patient ineligible for autologous transplantation
* Pregnant or lactating females
* Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to randomization
* Known human immunodeficiency virus infection (HIV)
* Active hepatitis A, B or C infection. Hepatitis C infection (subjects with hepatitis C that achieve a sustained virologic response after antiviral therapy are allowed), or hepatitis B infection (subjects with hepatitis B surface antigen or core antibody that achieve sustained virologic response with antiviral therapy are allowed). Tests to be performed if required per local country regulations. In fact it is not possible to avoid the risk of virological reactivation with the study treatments.
* Unstable angina or myocardial infarction within 4 months prior to randomization, NYHA Class III or IV heart failure, uncontrolled angina, uncontrolled hypertension, (Uncontrolled hypertension, defined as an average systolic blood pressure ≥ 160 mmHg or diastolic ≥ 100 mmHg despite optimal treatment (measured following European Society of Hypertension/European Society of Cardiology 2013 guidelines), pulmonary embolia, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker
* Non-hematologic malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas
* Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to randomization as defined by National Cancer Institute Common Toxicity Criteria (NCI CTCAE) 5.0
* Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib) and to PS80; prior hypersensitivity to sucrose, histidine (as base and hydrochloride salt), or any of the components (active substance or excipients) of study treatments that are not amenable to premedication with steroids, or H2 blockers, that would prohibit further treatment with these agents.
* Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
* Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent
* Pregnant or breastfeeding woman or woman who intends to become pregnant during the participation in the study. FCBP unwilling to prevent pregnancy by the use of 2 reliable methods of contraception for ≥4 weeks before the start of study treatment, during treatment (including dose interruptions), and for at least 28 days following discontinuation of study lenalidomide, or 30 days following discontinuation of carfilzomib or for 5 months after discontinuation of isatuximab treatment, whichever occurs last,
* Male participants who disagree to practice true abstinence or disagree to use a condom during sexual contact with a pregnant woman or a FCBP while participating in the study, during dose interruptions, and for at least 28 days following discontinuation of study lenalidomide, or 30 days following discontinuation of carfilzomib, or for 5 months after discontinuation of isatuximab treatment, whichever occurs last, even if he has undergone a successful vasectomy.

Primary outcomes:
measure: Rate of MRD negativity after ASCT consolidation treatment by NGS
timeFrame: The end of consolidation, average of 12 months
Secondary outcomes:
measure: Post induction MRD negativity rate by NGS
timeFrame: The end of induction, average of 4 months
measure: Progression-free survival (PFS) in the 2 arms
timeFrame: approximately up to 5 years
measure: Post light-consolidation MRD negativity rate by NGS
timeFrame: At the end of light-consolidation, average of 24 months
measure: Overall Response Rate (ORR) post-induction
timeFrame: Approx 4 months
measure: Overall Response Rate (ORR) post-transplant
timeFrame: Approximately 8 months
measure: Overall Response Rate (ORR) post-consolidation
timeFrame: Approximately 12 months
measure: Overall Response Rate (ORR) post light-consolidation
timeFrame: Approximately 24 months
measure: Post ASCT MRD negativity rate by NGS
timeFrame: After ASCT, approximately 8 months.
measure: MRD negativity rate by NGF post induction
timeFrame: Approximately 4 months
measure: MRD negativity rate by NGF post induction
timeFrame: Approximately 8 months
measure: MRD negativity rate by NGF post consolidation
timeFrame: Approximately 8 months
measure: MRD negativity rate by NGF post light consolidation
timeFrame: Approximately 24 months
measure: Duration of response
timeFrame: approximately up to 9 years
measure: Duration of MRD negativity (by NGS and NGF)
timeFrame: approximately up to 9 years
measure: Determine the rate of sustained for 1-year MRD negativity (by NGF and NGS) from post ASCT consolidation to post light consolidation
timeFrame: approximately up to 9 years
measure: Determine the time to progression (TTP)
timeFrame: approximately up to 9 years
measure: Overall Survival (OS)
timeFrame: approximately up to 9 years
measure: Time to next therapy (TNT)
timeFrame: approximately up to 9 years
measure: Progression-free survival on the next line of therapy (PFS2)
timeFrame: approximately up to 9 years
Other outcomes:
Locations:
city: Antwerp
country: Belgium
facility: Het Ziekenhuisnetwerk Antwerpen - Department of Hematology
city: Brno
country: Czechia
facility: Fakultni Nemocnice Brno - Internal Hematology and Oncology Clinic
city: Novy Hradec Kralove
country: Czechia
facility: Fakultni Nemocnice Hradec Kralove - 4th Department of Internal Medicine
city: Ostrava
country: Czechia
facility: Fakultni Nemocnice Ostrava - Department of Haematooncology
city: Prague
country: Czechia
facility: Vseobecna Fakultni Nemocnice V Praze - Internal Medicine, Hematology Clinic
city: Freiburg
country: Germany
facility: Medical Center - University Of Freiburg - Department Innere Medizin Klinik für Innere Medizin I
city: Hamburg
country: Germany
facility: University Medical Center Hamburg-Eppendorf - Medizinische Klinik und Polikllinik Onkologie und Knochenmarktransplantation, Haematologie
city: München
country: Germany
facility: Klinikum rechts der Isar der TU Muenchen AöR - Innere Medizin III-Haematologie/Onkologie
city: Athens
country: Greece
facility: Alexandra Hospital - Department of Clinical Therapeutics National & Kapodistrian University of Athens School of Medicine
city: Thessaloníki
country: Greece
facility: Theageneio General Hospital - Department of Hematology Oncology
city: Ancona
country: Italy
facility: Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I G M Lancisi G Salesi-SOD Clinica Ematologica
city: Bari
country: Italy
facility: University Hospital Consorziale Policlinico-U.O. di Ematologia con Trapianto
city: Bologna
country: Italy
facility: Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico - U.O. di Ematologia
city: Brescia
country: Italy
facility: Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia - UOC Ematologia
city: Cuneo
country: Italy
facility: Azienda Ospedaliera Santa Croce E Carle - S.C. Ematologia
city: Firenze
country: Italy
facility: Careggi University Hospital - SOD Ematologia
city: Novara
country: Italy
facility: Azienda Ospedaliero-Universitaria Maggiore Della Carita - SDCU Ematologia
city: Pavia
country: Italy
facility: Fondazione IRCCS Policlinico San Matteo-UOC Ematologia 1
city: Pescara
country: Italy
facility: Azienda Sanitaria Locale Di Pescara - U.O. Ematologia
city: Torino
country: Italy
facility: A.O.U. Città della Salute e della Scienza di Torino-U.O. Ematologia
city: Trieste
country: Italy
facility: Azienda Sanitaria Universitaria Giuliano Isontina-SC U.O.C Ematologia
city: Alkmaar
country: Netherlands
facility: Noordwest Ziekenhuisgroep Stichting - Internal Medicine - Hematology
city: Amersfoort
country: Netherlands
facility: Meander Medisch Centrum -Internal Medicine - Hematology
city: Amsterdam
country: Netherlands
facility: Amsterdam-Vrije Universiteit Medical Center (VUMC)
city: Breda
country: Netherlands
facility: Amphia Hospital-Internal Medicine - Hematology
city: Dordrecht
country: Netherlands
facility: Albert Schweitzerplaats 25
city: Geleen
country: Netherlands
facility: Zuyderland Medisch Centrum Stichting - Internal Medicine - Hematology
city: Groningen
country: Netherlands
facility: Universitair Medisch Centrum Groningen-Department of Haematology
city: Leeuwarden
country: Netherlands
facility: Medisch Centrum Leeuwarden B.V. - Oncologisch Centrum Leeuwarden (OCL) and Internal Medicine - Hematology
city: Nieuwegein
country: Netherlands
facility: Sint Antonius Ziekenhuis Stichting-Internal Medicine - Hematology
city: Rotterdam
country: Netherlands
facility: ErasmusMC, Rotterdam-Department of Hematology
city: s-Gravenweg
country: Netherlands
facility: Haga Hospital - Internal Medicine - Hematology
city: Oslo
country: Norway
facility: Oslo University Hospital HF - Oslo myelomatosesenter
city: Trondheim
country: Norway
facility: St. Olavs Hospital HF - Department of Hematology
city: Badalona
country: Spain
facility: Hospital Germans Trias I Pujol - Hematology Service ICO Badalona Clinic
city: Barcelona
country: Spain
facility: Hospital Clinic De Barcelona - Myeloma and Amyloidosis Unit
city: Madrid
country: Spain
facility: Hospital Universitario 12 De Octubre - Hematology
city: Madrid
country: Spain
facility: Hospital Universitario 12 De Octubre -Hematology and Hemotherapy Service
city: Pamplona
country: Spain
facility: Clinica Universidad De Navarra - Central Clinical Trials Unit
city: Salamanca
country: Spain
facility: Hospital Universitario De Salamanca-Department of Hematology of the Salamanca University Care Complex
city: Santander
country: Spain
facility: Hospital Universitario Marques De Valdecilla -Hematology and Hemotherapy Service
Study officials:
References: